Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021

Clearance of IND by FDA and clinical trial start-up for P-BCMA-ALLO1 begins planned strategic shift to allogeneic BCMA CAR-T program for patients with multiple myeloma; P-BCMA-101 autologous CAR-T program to be wound down

Presented strong data in the quarter on P-PSMA-101 program in prostate cancer demonstrating the potential advantages of high TSCM CAR-T products in solid tumors

Announced research collaboration with Takeda for use of Poseida’s platform technologies to develop non-viral liver- and HSC-directed in vivo gene therapies

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the third quarter ended September 30, 2021.